Aclaris Therapeutics (ACRS) Receivables (2017 - 2025)
Aclaris Therapeutics' Receivables came in at $194,000 for Q2 2025, down 40.3% from $325,000 a year earlier and down 22.4% from the prior quarter.
Powered by 
Analysis
Aclaris Therapeutics (ACRS) Receivables (2017 - 2025) Analysis & Trends
At the end of FY2024, Aclaris Therapeutics' Receivables was $318,000, up 6.7% from FY2023.
- Receivables carries a five-year compound annual growth rate of -16.9% (FY2019 to FY2024).
- Going back by year, Receivables was $298,000 in FY2023 (-38.4%), $484,000 in FY2022 (-25.2%), $647,000 in FY2021 (-39.6%) and $1.07 million in FY2020 (+33.3%).
- The Q2 2025 figure represents the lowest quarterly Receivables in data going back to Q3 2017.
- Year-over-year, Receivables increased in 1 of the last eight quarters, with an average decline of 27.3%.
- The fastest year-over-year change in Receivables over five years came in Q3 2020 (growth of 53.6%), and the weakest in Q1 2024 (a decline of 45.6%).
- Business Quant data shows ACRS's Receivables at $250,000 (Q1 2025), $318,000 (Q4 2024) and $343,000 (Q3 2024) in the three quarters before Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 15.68 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 10.23 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 5.06 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 12.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 2.13 Bn |
| 10 | Aclaris Therapeutics | 759.25 Mn | 759.25 Mn | 1.41 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 194,000.00 |
| Mar 31, 2025 | 250,000.00 |
| Dec 31, 2024 | 318,000.00 |
| Sep 30, 2024 | 343,000.00 |
| Jun 30, 2024 | 325,000.00 |
| Mar 31, 2024 | 373,000.00 |
| Dec 31, 2023 | 298,000.00 |
| Sep 30, 2023 | 346,000.00 |
| Jun 30, 2023 | 431,000.00 |
| Mar 31, 2023 | 686,000.00 |
| Dec 31, 2022 | 484,000.00 |
| Sep 30, 2022 | 597,000.00 |
| Jun 30, 2022 | 637,000.00 |
| Mar 31, 2022 | 633,000.00 |
| Dec 31, 2021 | 647,000.00 |
| Sep 30, 2021 | 835,000.00 |
| Jun 30, 2021 | 963,000.00 |
| Mar 31, 2021 | 837,000.00 |
| Dec 31, 2020 | 1.07 Mn |
| Sep 30, 2020 | 1.19 Mn |
API Access
Aclaris Therapeutics Receivables API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables&ticker=ACRS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables", "ticker": "ACRS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=receivables&ticker=ACRS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();